作者: Almeida, Dennys Ramon de Melo Fernandes ; Santos, Pedro Paulo de Andrade ; de França, Glória Maria ; Pinheiro, Juliana Campos ; Lima, Jabes Gennedyr da Cruz ; Medeiros, Cristianne Kalinne Santos

AbstractIntroductionSeveral treatments have been used to reduce inflammation and to reverse epithelial alterations in actinic cheilitis (AC).AimA systematic review was conducted to analyze the potential of topical treatments for remission and clinical improvement of AC as well as patient acceptability.MethodsA systematic review of clinical trials was conducted following the PICO strategy to answer the following question: Are topical anti‐inflammatory and antineoplastic agents effective in the treatment of actinic cheilitis? The quality of the studies was assessed by ROB‐2, and the certainty of evidence was rated by GRADE guidelines.ResultsEight clinical trials were selected, including four that investigated the use of anti‐inflammatory drugs and four use of antineoplastic agents. The use of 3% diclofenac sodium was associated with partial remission of AC, while 5% imiquimod and ingenol mebutate promoted complete remission. Furthermore, 5% fluorouracil was the drug most associated with complications during treatment. Diclofenac sodium (3%) and fludroxycortide showed the best acceptance by the patients, especially in terms of symptom relief and comfort provided.ConclusionThe anti‐inflammatory and antineoplastic agents analyzed largely provided good clinical outcomes, with evidence of remission of AC lesions, development of few local adverse reactions during treatment, and good patient adherence.

2020-08-01·Dermatologic Surgery3区 · 医学

Combination of 1,064-nm Neodymium-doped Yttrium Aluminum Garnet Laser and Steroid Tape Decreases the Total Treatment Time of Hypertrophic Scars: An Analysis of 40 Cases of Cesarean-Section Scars

3区 · 医学

Article

作者: An-Jou Lin, Jennifer ; Tsai, Chia-Hsuan ; Ogawa, Rei ; Akaishi, Satoshi ; Kao, Huang-Kai

BACKGROUNDThe 1,064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (Cutera, Inc., Brisbane, CA) and steroid tape (fludroxycortide tape) have been used to treat keloids and hypertrophic scars.OBJECTIVETo evaluate the efficacy of contact-mode 1,064-nm Nd:YAG laser therapy and steroid tape for hypertrophic cesarean-section scars versus conservative therapy (steroid tape only).MATERIALS AND METHODSA medical record review identified 40 consecutive Japanese patients who had hypertrophic scars (total Japan Scar Workshop Scar Scale [JSS] 2015 evaluation scores of 9 to 12) for more than 1 year after a vertical cesarean section and who were treated at our scar-specialist clinic from July 2015 to December 2017. All 40 patients continued treatment until the total JSS score dropped below 3. Recurrence was defined as a ≥1-point increase in the total JSW score 6 months after achieving a total JSS score <3.RESULTSThe patients had a mean age of 34.2 years. The test (n = 25) and control (n = 15) groups took on average 16.9 and 24.3 months to achieve a total JSS score <3, respectively (p < .01). In the following 6 months, none of the scars recurred.CONCLUSIONNd:YAG laser treatment effectively decreased the total treatment time of hypertrophic cesarean-section scars. An algorithm for treating mild and severe hypertrophic cesarean-section scars is proposed.

2019-10-01·Clinical Oral Investigations2区 · 医学

Fludroxycortide cream as an alternative therapy for actinic cheilitis

2区 · 医学

Article

作者: Gonzaga, Amanda Katarinny Goes ; de Oliveira, Patrícia Teixeira ; da Silveira, Éricka Janine Dantas ; de Medeiros, Ana Miryam Costa ; de Oliveira Bezerra, Hanna Isa

OBJECTIVESThe objective of the study is to assess, by clinical follow-up, the efficacy of the dermatological cream Fludroxycortide 0.125 mg/g (Drenison®) in the treatment of actinic cheilitis (AC).MATERIAL AND METHODSTwenty-three patients diagnosed with AC participated in the study. Fifteen were submitted to corticotherapy with Fludroxycortide, applied three times a day for up to 6 weeks, associated with lip sunscreen (LS) before sun exposure. In the control group of eight patients, only the use of LS was established. At each weekly return, a photographic record was made of the lesion. After treatment, images were evaluated and scores were assigned to verify clinical evolution. Also, patients treated with Fludroxycortide responded to a questionnaire, to assess drug tolerability and treatment satisfaction.RESULTSIn the group treated with Fludroxycortide (n = 15), five patients showed total improvement, seven presented partial improvement, and three showed no clinical change. Concerning the patients treated with LS (n = 8), one presented total remission of the clinical lesion characteristics, four exhibited partial improvement, and three exhibited no clinical lip alteration. No case presented symptom worsening. Of the 15 patients undergoing corticotherapy, 12 were satisfied and reported that the product was not irritating and contributed to lesion improvement.CONCLUSIONSConventional treatment with LS was effective in the remission of some AC lesions, but treatment responses were improved when associated with Fludroxycortide, especially in the more severe cases.CLINICAL RELEVANCEAs it is a non-invasive therapy leading, in most cases, to adequate clinical results, safety, and tolerability, Fludroxycortide can be considered an effective alternative treatment for AC.

100 项与氟氢缩松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00328	氟氢缩松	D07AC07	DB00846

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
原发性皮肤淀粉样变性	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
皮肤增生性瘢痕	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
Fox-Fordyce病	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
环形肉芽肿	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
瘢痕疙瘩	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
光泽苔癣	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
淋巴瘤	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
白癜风	日本	Sumitomo Pharma Co., Ltd.	1981-08-31
湿疹	日本	Sumitomo Pharma Co., Ltd.	1972-04-01
扁平苔藓	日本	Sumitomo Pharma Co., Ltd.	1972-04-01
盘状红斑狼疮	日本	Sumitomo Pharma Co., Ltd.	1972-04-01
结节性痒疹	日本	Sumitomo Pharma Co., Ltd.	1972-04-01
银屑病	日本	Sumitomo Pharma Co., Ltd.	1972-04-01